For investors looking to join the momentum of a technical breakout with the basic strength of a company with sound fundamentals, a method centered on solid growth stocks with encouraging technical formations can be persuasive. This method tries to find companies that are not only increasing their earnings and revenue at a notable rate but are also near a possible price increase as shown by chart formations. By selecting for stocks with high growth scores, good profitability, and financial stability, investors can aim at businesses with the capacity to maintain an upward move. Then, by adding a technical study that finds periods of stability and breakout formations, the method tries to determine an entry point, searching for a trigger that might push the stock upward. This two-part technique tries to join the "what" of a good company with the "when" of market entry timing.
Neurocrine Biosciences Inc. (NASDAQ:NBIX) offers a present example for this investment idea. The biotechnology company, centered on neurological and endocrine disorders, shows the solid fundamental growth outline that acts as the base for this method, while its recent price movement displays the technical formations that indicate a possible turning point.
Fundamental Growth Capacity
The center of the method requires a company with a clear and provable growth path. Neurocrine’s fundamental report shows a business performing well in this area, receiving a high ChartMill Growth Rating of 9 out of 10. This score is formed on outstanding past results and encouraging future projections.
- Strong Past Growth: Over the last year, Neurocrine's Earnings Per Share (EPS) increased by 41.64%, while Revenue grew by 21.45%. The longer-term view is also solid, with an average yearly EPS growth of 29.09% and Revenue growth of 22.29% over recent years.
- Continued Future Projections: Analysts expect this progress to persist, with an estimated average yearly EPS growth of 26.83% and Revenue growth of 10.12% in the next years. This forward-looking belief is important, as the method focuses on companies whose growth narratives are current, not only past.
Beyond pure growth, the method selects for profitability and financial health to confirm the company is run well and on stable ground. Neurocrine scores a 7 in both Profitability and Health. Main strengths include a notable Profit Margin of 16.73% and an Operating Margin of 22.25%, which place in the top group of its biotechnology industry. Financially, the company has no debt and has a strong Altman-Z score of 7.25, showing very low bankruptcy risk and good liquidity with a Current Ratio above 3. This pairing indicates the company's growth is of good quality and can be maintained, supporting itself through operations instead of high debt.
You can examine the complete details of this study in Neurocrine’s fundamental report.
Technical Formation for a Breakout
While solid fundamentals give the "fuel," the technical formation looks for the "trigger" – a chart formation hinting the stock is getting ready to move. Neurocrine’s technical rating is now low, pulled down by negative short and long-term trends that match the wider market decline. However, the more detailed ChartMill Setup Rating is an encouraging 8 out of 10, pointing out a specific stability formation inside the wider downward trend.
The stock has been moving in a fairly wide band over the last month, between about $125 and $135, and is now positioned near the bottom of that band. This stability near recent lows, after a drop, can sometimes mark a basing formation where selling is met with buying. Importantly, the study finds a set support area just below the present price, from $123.10 to $125.42, created by several trend lines. The existence of this support level is central to the breakout idea; it gives a clear technical bottom. The formation hints that if the stock can maintain this support and start to move up, it may test the nearby overhead resistance between $128.65 and $130.07. A clear move above this resistance area on higher volume could mark the beginning of a new upward phase, possibly giving an entry point for momentum-focused investors.
For a picture of these support and resistance levels, see Neurocrine’s technical analysis report.
A Unified Investment Idea
The reason for joining these standards is clear: a solid growth stock in a technical stability phase marks a possible chance. The high-growth fundamentals of Neurocrine Biosciences give a persuasive reason for investor attention and a fundamental basis for a higher stock price with time. The present technical formation, described by stability above a set support level after a decline, finds a moment where that fundamental possibility may start to be seen by the wider market. The method suggests that when a fundamentally strong company stops falling and starts to base, it may be getting ready for its next rise.
Neurocrine Biosciences shows the kind of company this search tries to find—one with the financial strength and growth numbers to support a notable revaluation, currently showing a chart formation that technical analysts monitor for a possible turn or breakout.
Interested in finding other stocks that match this outline of solid growth paired with an encouraging technical formation? You can use the "Strong Growth Stock Technical Setups" search yourself to see the newest results here.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation, or an offer or solicitation to buy or sell any securities. The analysis presented is based on data and reports provided by third parties. Investing in stocks involves risk, including the potential loss of principal. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results.